Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Story

YuanShi Technology Raises Nearly RMB 300M for AI Virtual Cells

AI summary

Shanghai AI drug-discovery startup YuanShi Technology announced nearly RMB 300 million in Pre-A funding led by Legend Capital, with ChinaAMC, a JD.com affiliate fund and CMC Capital among the investors. The company plans to use the proceeds to collect cell-intervention data, build an automated experimental platform, iterate its general cell foundation model and expand its research team. YuanShi Technology says its virtual-cell models predict cellular responses across disease states, experimental conditions and interventions, then use experimental results to train and update the models.

In-depth insight

The financing provides substantial capital for an AI virtual-cell company building a data-and-experiment feedback loop, while its claimed financing record remains unverified.

智东西 作者 | 孙小雯 编辑 | 程茜

智东西11月19日消息,今日,上海AI制药创企元示科技宣布,完成近3亿元人民币Pre-A轮融资,并宣称刷新国内AI虚拟细胞(AIVC)领域的单笔融资纪录。

这是元示科技近一个月内官宣的第三轮融资,本轮融资由君联资本领投,华夏瓴投、京东关联基金、CMC资本等跟投,光源资本担任独家财务顾问。今年10月,元示科技宣布已连续完成近亿元人民币天使轮及天使+轮融资。

该公司计划将新资金主要用于积累细胞干预与响应数据、建设自动化实验平台、迭代通用细胞大模型及扩充研发团队。

元示科技于今年4月成立,主要研发AI虚拟细胞模型,旨在预测细胞在不同疾病状态、实验条件和干预方式下的响应。此外,该公司同步建设实验数据生产体系,通过实验检验模型预测,并将结果用于后续训练与更新。该公司称,这一迭代过程为递归自我改进(RSI)在生物基础模型中的应用。

#YuanShi Technology#Legend Capital#ChinaAMC#JD.com#CMC Capital#Lighthouse Capital#MGI Tech#Yongsheng Intelligence#AI virtual cell models

Original · 3 min readRead the original
Group chat

No comments yet. Start the conversation.